User login
Key clinical point: Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly decreased postoperative peritoneal recurrence and prolonged survival in patients with clinical T4 gastric cancer who underwent gastrectomy with lymphadenectomy.
Major finding: Prophylactic HIPEC vs no HIPEC significantly lowered the overall recurrence rate (34.3% vs 62.9%; P = .04) and postoperative peritoneal carcinomatosis (21.7% vs 57.1%; P = .03). HIPEC significantly improved the overall survival (OS) rate (71.4% vs 40.0%; P = .01). Patients in the HIPEC group had a significantly longer OS (adjusted hazard ratio [aHR] 0.37; P = .035) and disease-free survival (aHR 0.33; P = .017).
Study details: This was a retrospective study of 132 patients with clinical stage T4 gastric cancer who underwent gastrectomy plus D2 lymphadenectomy between 2014 and 2020. Thirty-five of the 132 patients received prophylactic HIPEC perioperatively.
Disclosures: No funding source was identified for this work. The authors declared no competing interests.
Source: Lee TY et al. Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer. Eur J Surg Oncol. 2022 (Apr 27). Doi: 10.1016/j.ejso.2022.04.018
Key clinical point: Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly decreased postoperative peritoneal recurrence and prolonged survival in patients with clinical T4 gastric cancer who underwent gastrectomy with lymphadenectomy.
Major finding: Prophylactic HIPEC vs no HIPEC significantly lowered the overall recurrence rate (34.3% vs 62.9%; P = .04) and postoperative peritoneal carcinomatosis (21.7% vs 57.1%; P = .03). HIPEC significantly improved the overall survival (OS) rate (71.4% vs 40.0%; P = .01). Patients in the HIPEC group had a significantly longer OS (adjusted hazard ratio [aHR] 0.37; P = .035) and disease-free survival (aHR 0.33; P = .017).
Study details: This was a retrospective study of 132 patients with clinical stage T4 gastric cancer who underwent gastrectomy plus D2 lymphadenectomy between 2014 and 2020. Thirty-five of the 132 patients received prophylactic HIPEC perioperatively.
Disclosures: No funding source was identified for this work. The authors declared no competing interests.
Source: Lee TY et al. Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer. Eur J Surg Oncol. 2022 (Apr 27). Doi: 10.1016/j.ejso.2022.04.018
Key clinical point: Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly decreased postoperative peritoneal recurrence and prolonged survival in patients with clinical T4 gastric cancer who underwent gastrectomy with lymphadenectomy.
Major finding: Prophylactic HIPEC vs no HIPEC significantly lowered the overall recurrence rate (34.3% vs 62.9%; P = .04) and postoperative peritoneal carcinomatosis (21.7% vs 57.1%; P = .03). HIPEC significantly improved the overall survival (OS) rate (71.4% vs 40.0%; P = .01). Patients in the HIPEC group had a significantly longer OS (adjusted hazard ratio [aHR] 0.37; P = .035) and disease-free survival (aHR 0.33; P = .017).
Study details: This was a retrospective study of 132 patients with clinical stage T4 gastric cancer who underwent gastrectomy plus D2 lymphadenectomy between 2014 and 2020. Thirty-five of the 132 patients received prophylactic HIPEC perioperatively.
Disclosures: No funding source was identified for this work. The authors declared no competing interests.
Source: Lee TY et al. Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer. Eur J Surg Oncol. 2022 (Apr 27). Doi: 10.1016/j.ejso.2022.04.018